A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Papulopustular Rosacea
In brief
This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.
Key facts
- Study ID
- NCT07681271
- Run by
- Novartis Pharmaceuticals
- People needed
- 80
- Starts
- 2026-07-30
- Expected to finish
- 2027-12-07
- Last updated by the study team
- 2026-08-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Three A Research — El Paso, Texas, United States (enrolling)
- Novartis Investigative Site — London, Ontario, Canada (enrolling)
- Novartis Investigative Site — Dongjak Gu, Seoul, South Korea (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.